Antiviral pioneer Gilead Sciences is expected to report fourth-quarter earnings results on Tuesday after the closing bell. A Zacks Rank #3 (Hold) stock, Gilead surpassed earnings estimates in three of the past four quarters. With the stock showing momentum this year, is GILD a buy ahead of the release?
Find the latest EPS estimates and surprises on Zacks Earnings Calendar.
Analysts expect the company to post a profit of $1.83 per share, reflecting a -3.7% decline versus the same quarter in the prior year. Estimates for the quarter have come down slightly over the past 60 days. Revenues are projected to rise 0.07% to $7.57 billion.
The drug developer posted a trailing four-quarter average earnings surprise of 7.8%. Its market-leading HIV franchise has fueled top-line growth. Gilead GILD has also diversified into the lucrative oncology market.
Shares remain undervalued relative to industry peers. The stock is outperforming in 2026 with a 22% return year-to-date.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners UpGilead Sciences, Inc. (GILD) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
